Eton Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Eton Pharmaceuticals, Inc. on July 31, 2026. The filing addresses Item 5.02 regarding the appointment of a new executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and compensation arrangements.
Material Changes
On July 31, 2026, the Company appointed Danka Radosavljevic as Chief Operating Officer (COO). Ms. Radosavljevic, who has been with the Company since 2017, previously served as Executive Vice President, Operations, overseeing quality, product development, regulatory affairs, supply chain, and information systems for over five years.
Management Commentary and Compensation
Ms. Radosavljevic's new compensation package includes:
- Annual Base Salary: $520,800
- Annual Discretionary Incentive Bonus: Target amount of 50% of base salary, contingent on corporate and/or individual performance targets approved by the Board of Directors.
The filing does not contain specific guidance, outlook, risks, contingencies, or unusual items beyond the executive appointment.
Investor Verification Checklist
- Verify the effective date of the COO appointment (July 31, 2026).
- Confirm the total potential annual compensation value ($520,800 base + up to $260,400 bonus).
- Review the specific performance targets for the discretionary bonus once approved by the Board.
- Check subsequent filings for any changes to the executive team or compensation structure.